Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Caribou Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BERKELEY, CALIF., DEC. 01, 2025 (GLOBE NEWSWIRE) -- CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU), A LEADING CLINICAL-STAGE CRISPR GENOME-EDITING BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT IT WILL HOST AN EXPERT PHYSICIAN PANEL DISCUSSION DURING AN ANCILLARY EVENT AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION. THE SESSION WILL FOCUS ON HOW VISPA-CEL, CARIBOU'S ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY, HAS THE POTENTIAL TO EXPAND PATIENT ACCESS BY ENABLING READILY AVAILABLE CAR-T CELL THERAPY CARE WITHIN SOPHISTICATED COMMUNITY HOSPITALS AND ACADEMIC CENTERS.

CARIBOU BIOSCIENCES TO HOST IN-PERSON AND VIRTUAL KOL EVENT AT ASH 2025

VISPA-CEL (CB-010) ANTLER PHASE 1 DATA DEMONSTRATE EFFICACY AND DURABILITY ON PAR WITH AUTOLOGOUS CAR-T CELL THERAPY AND SAFETY ALLOWS FOR OUTPATIENT USE, HIGHLIGHTING ITS POTENTIAL AS A BEST-IN-CLASS ALLOGENEIC CAR-T CELL THERAPY FOR LBCL CB-011 CAMMOUFLAGE PHASE 1 DATA DEMONSTRATE DEEP, DURABLE RESPONSES AND MANAGEABLE SAFETY, HIGHLIGHTING ITS POTENTIAL AS A BEST-IN-CLASS ALLOGENEIC CAR-T CELL THERAPY FOR R/R MULTIPLE MYELOMA $159.2 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES AS OF SEPTEMBER 30, 2025 BERKELEY, CALIF., NOV. 12, 2025 (GLOBE NEWSWIRE) -- CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU), A LEADING CLINICAL-STAGE CRISPR GENOME-EDITING BIOPHARMACEUTICAL COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER 2025 AND PROVIDED AN OVERVIEW OF RECENT CORPORATE HIGHLIGHTS.

CARIBOU BIOSCIENCES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BERKELEY, CALIF., NOV. 03, 2025 (GLOBE NEWSWIRE) -- CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU), A LEADING CLINICAL-STAGE CRISPR GENOME-EDITING BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES:

CARIBOU BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

DATA DEMONSTRATE EFFICACY AND DURABILITY OF VISPA-CEL, AN ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY, ARE ON PAR WITH AUTOLOGOUS CAR-T CELL THERAPIES IN THE CONFIRMATORY COHORT (N=22) AND WITH LONGER-TERM FOLLOW-UP ON PATIENTS WHO RECEIVED OPTIMIZED VISPA-CEL (N=35) 82% ORR, 64% CR RATE, 51% PFS AT 12 MONTHS IN PATIENTS PROSPECTIVELY ENROLLED IN PARTIAL HLA MATCHING CONFIRMATORY COHORT (N=22) 86% ORR, 63% CR RATE, 53% PFS AT 12 MONTHS IN PATIENTS WHO RECEIVED VISPA-CEL WITH AN OPTIMIZED PROFILE (N=35) VISPA-CEL IS GENERALLY WELL-TOLERATED, ALLOWING FOR ADMINISTRATION IN THE OUTPATIENT SETTING DATA HIGHLIGHT VISPA-CEL'S POTENTIAL AS BEST-IN-CLASS ALLOGENEIC CAR-T CELL THERAPY FOR LBCL CONFERENCE CALL AND WEBCAST SCHEDULED FOR TODAY AT 8:00 AM ET BERKELEY, CALIF., NOV. 03, 2025 (GLOBE NEWSWIRE) -- CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU), A LEADING CLINICAL-STAGE CRISPR GENOME-EDITING BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED POSITIVE RESULTS FROM ITS ONGOING ANTLER PHASE 1 CLINICAL TRIAL EVALUATING VISPACABTAGENE REGEDLEUCEL (VISPA-CEL; FORMERLY CB-010), AN ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (R/R B-NHL).

CARIBOU BIOSCIENCES ANNOUNCES POSITIVE DATA FROM ANTLER PHASE 1 TRIAL DEMONSTRATING EFFICACY AND DURABILITY OF VISPA-CEL (CB-010), AN ALLOGENEIC CAR-T CELL THERAPY, ON PAR WITH AUTOLOGOUS CAR-T CELL THERAPIES

BERKELEY, CALIF., NOV. 03, 2025 (GLOBE NEWSWIRE) -- CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU), A LEADING CLINICAL-STAGE CRISPR GENOME-EDITING BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED ITS FIRST CLINICAL DATA FROM DOSE ESCALATION IN THE ONGOING CAMMOUFLAGE PHASE 1 TRIAL EVALUATING CB-011, AN OFF-THE-SHELF ANTI-BCMA CAR-T CELL THERAPY, IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R/R MM), HIGHLIGHTING CB-011 AS A POTENTIALLY BEST-IN-CLASS ALLOGENEIC CAR-T CELL THERAPY FOR THIS PATIENT POPULATION. THE COMPANY IS ADVANCING THE PROGRAM INTO DOSE EXPANSION, WHICH IT EXPECTS TO INITIATE BY THE END OF THIS YEAR, AND THE COMPANY PLANS TO SHARE DOSE EXPANSION DATA IN 2026.

CARIBOU BIOSCIENCES ANNOUNCES POSITIVE DATA FROM CAMMOUFLAGE PHASE 1 TRIAL OF CB-011 IN MULTIPLE MYELOMA

BERKELEY, CALIF., NOV. 02, 2025 (GLOBE NEWSWIRE) -- CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU), A LEADING CLINICAL-STAGE CRISPR GENOME-EDITING BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT IT WILL HOLD A WEBCAST BEGINNING AT 8:00 AM ET ON MONDAY, NOVEMBER 3, 2025, TO REPORT NEW DATA FROM THE ANTLER PHASE 1 CLINICAL TRIAL EVALUATING VISPACABTAGENE REGEDLEUCEL (VISPA-CEL; FORMERLY CB-010), AN ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (R/R B-NHL) AND REPORT THE FIRST CLINICAL DATA FROM THE CAMMOUFLAGE PHASE 1 CLINICAL TRIAL EVALUATING CB-011, AN ALLOGENEIC ANTI-BCMA CAR-T CELL THERAPY, IN PATIENTS WITH R/R MULTIPLE MYELOMA. THE COMPANY WILL ALSO REPORT ITS ANTICIPATED PIVOTAL PHASE 3 TRIAL DESIGN FOR VISPA-CEL AND NEXT STEPS FOR THE CONTINUED CLINICAL DEVELOPMENT OF CB-011.

CARIBOU BIOSCIENCES TO HOST WEBCAST TO REPORT NEW DATA UPDATES FROM TWO ALLOGENEIC CAR-T CELL THERAPY PROGRAMS IN LYMPHOMA AND MULTIPLE MYELOMA

BERKELEY, CALIF., AUG. 25, 2025 (GLOBE NEWSWIRE) -- CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU), A LEADING CLINICAL-STAGE CRISPR GENOME-EDITING BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED RACHEL HAURWITZ, PHD, CARIBOU'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE CITI 2025 BIOPHARMA BACK TO SCHOOL CONFERENCE ON SEPTEMBER 3, 2025 AT 2:30 PM EDT.

CARIBOU BIOSCIENCES TO PARTICIPATE IN THE CITI 2025 BIOPHARMA BACK TO SCHOOL CONFERENCE

-- TWO ROBUST CLINICAL DATASETS FROM CB-010 AND CB-011 EXPECTED TO BE DISCLOSED IN H2 2025 -- -- $184 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES EXPECTED TO FUND THE COMPANY'S CURRENT OPERATING PLAN INTO H2 2027 -- BERKELEY, CALIF., AUG. 12, 2025 (GLOBE NEWSWIRE) -- CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU), A LEADING CLINICAL-STAGE CRISPR GENOME-EDITING BIOPHARMACEUTICAL COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND PROVIDED A BUSINESS UPDATE FOR ITS ONCOLOGY CLINICAL PROGRAMS CB-010 AND CB-011 WITH DATA DISCLOSURES ON TRACK FOR H2 2025.

CARIBOU BIOSCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BERKELEY, CALIF., MAY 28, 2025 (GLOBE NEWSWIRE) -- CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU), A LEADING CLINICAL-STAGE CRISPR GENOME-EDITING BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED RACHEL HAURWITZ, PHD, CARIBOU'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON JUNE 4TH AT 9:20 AM EDT.

CARIBOU BIOSCIENCES TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

-- TWO ROBUST CLINICAL DATASETS FROM CB-010 AND CB-011 EXPECTED TO BE DISCLOSED IN H2 2025 -- -- $212.5 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES EXPECTED TO FUND THE COMPANY'S CURRENT OPERATING PLAN INTO H2 2027 -- BERKELEY, CALIF., MAY 08, 2025 (GLOBE NEWSWIRE) -- CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU), A LEADING CLINICAL-STAGE CRISPR GENOME-EDITING BIOPHARMACEUTICAL COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER 2025 AND PROVIDED A BUSINESS UPDATE FOR ITS LEAD ONCOLOGY CLINICAL PROGRAMS CB-010 AND CB-011 WITH DATA DISCLOSURE FOR EACH PLANNED FOR H2 2025.

Caribou Biosciences, Inc.

CRBU

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Caribou Biosciences, Inc.

CRBU.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CRBU